| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 214 | 2024 | 6982 | 12.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 78 | 2024 | 2899 | 9.090 |
Why?
|
| Graft vs Host Disease | 89 | 2024 | 2804 | 6.890 |
Why?
|
| Transplantation Conditioning | 95 | 2024 | 2359 | 6.510 |
Why?
|
| Transplantation, Homologous | 79 | 2024 | 3033 | 3.230 |
Why?
|
| Busulfan | 31 | 2023 | 786 | 3.190 |
Why?
|
| Multiple Myeloma | 43 | 2024 | 2321 | 3.120 |
Why?
|
| Immunotherapy, Adoptive | 40 | 2024 | 1838 | 3.030 |
Why?
|
| Antigens, CD19 | 28 | 2024 | 584 | 2.910 |
Why?
|
| Leukemia, Myeloid, Acute | 66 | 2024 | 7240 | 2.750 |
Why?
|
| Philadelphia Chromosome | 24 | 2024 | 834 | 2.290 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 8 | 2019 | 204 | 2.290 |
Why?
|
| Hepatic Veno-Occlusive Disease | 7 | 2024 | 135 | 2.180 |
Why?
|
| Transplantation, Autologous | 51 | 2024 | 2049 | 2.110 |
Why?
|
| T-Lymphocytes | 29 | 2023 | 3928 | 1.940 |
Why?
|
| Neoplasm, Residual | 29 | 2024 | 1740 | 1.940 |
Why?
|
| Myeloablative Agonists | 17 | 2022 | 386 | 1.870 |
Why?
|
| Adult | 203 | 2024 | 81523 | 1.680 |
Why?
|
| Cyclophosphamide | 36 | 2024 | 3231 | 1.620 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2023 | 504 | 1.610 |
Why?
|
| Hematologic Neoplasms | 24 | 2022 | 1955 | 1.610 |
Why?
|
| Recurrence | 50 | 2024 | 4879 | 1.600 |
Why?
|
| Melphalan | 26 | 2023 | 877 | 1.580 |
Why?
|
| Cord Blood Stem Cell Transplantation | 15 | 2023 | 372 | 1.540 |
Why?
|
| Myelodysplastic Syndromes | 30 | 2024 | 3145 | 1.500 |
Why?
|
| Humans | 349 | 2024 | 270757 | 1.490 |
Why?
|
| Remission Induction | 40 | 2024 | 3645 | 1.430 |
Why?
|
| Stem Cell Transplantation | 23 | 2023 | 1424 | 1.430 |
Why?
|
| Receptors, Antigen, T-Cell | 19 | 2023 | 1135 | 1.410 |
Why?
|
| Unrelated Donors | 15 | 2024 | 321 | 1.410 |
Why?
|
| Middle Aged | 193 | 2024 | 90004 | 1.340 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 15 | 2023 | 1734 | 1.330 |
Why?
|
| DNA Transposable Elements | 4 | 2017 | 252 | 1.200 |
Why?
|
| Antibodies, Bispecific | 7 | 2023 | 274 | 1.200 |
Why?
|
| Vidarabine | 25 | 2022 | 1383 | 1.180 |
Why?
|
| Aged | 157 | 2024 | 73156 | 1.160 |
Why?
|
| Young Adult | 85 | 2024 | 22044 | 1.150 |
Why?
|
| Adolescent | 92 | 2024 | 32515 | 1.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2023 | 16593 | 1.130 |
Why?
|
| Salvage Therapy | 15 | 2023 | 2117 | 1.110 |
Why?
|
| Retrospective Studies | 101 | 2024 | 39670 | 1.080 |
Why?
|
| Acute Disease | 20 | 2024 | 2513 | 1.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 7 | 2023 | 1068 | 0.980 |
Why?
|
| Lymphoma, B-Cell | 7 | 2024 | 935 | 0.960 |
Why?
|
| Allografts | 20 | 2024 | 684 | 0.960 |
Why?
|
| Male | 173 | 2024 | 128346 | 0.950 |
Why?
|
| Disease-Free Survival | 45 | 2021 | 10249 | 0.930 |
Why?
|
| Vascular Diseases | 2 | 2024 | 243 | 0.900 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 3393 | 0.880 |
Why?
|
| Arabinonucleosides | 6 | 2017 | 458 | 0.880 |
Why?
|
| Female | 173 | 2024 | 148398 | 0.870 |
Why?
|
| Survival Analysis | 44 | 2023 | 9304 | 0.860 |
Why?
|
| Chromosome Aberrations | 14 | 2024 | 2022 | 0.810 |
Why?
|
| Adenine Nucleotides | 5 | 2016 | 365 | 0.800 |
Why?
|
| Histocompatibility Testing | 13 | 2024 | 483 | 0.800 |
Why?
|
| Treatment Outcome | 78 | 2024 | 33785 | 0.790 |
Why?
|
| Lymphocyte Depletion | 5 | 2024 | 311 | 0.770 |
Why?
|
| Whole-Body Irradiation | 4 | 2017 | 324 | 0.750 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2018 | 609 | 0.750 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 13 | 2021 | 2633 | 0.730 |
Why?
|
| Receptors, Antigen | 5 | 2015 | 68 | 0.720 |
Why?
|
| Dexamethasone | 20 | 2023 | 1506 | 0.710 |
Why?
|
| Protein Kinase Inhibitors | 12 | 2024 | 4956 | 0.700 |
Why?
|
| Survival Rate | 39 | 2024 | 12516 | 0.690 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2019 | 319 | 0.680 |
Why?
|
| Antigens, Neoplasm | 5 | 2023 | 1589 | 0.660 |
Why?
|
| Cystitis | 2 | 2021 | 109 | 0.620 |
Why?
|
| Antineoplastic Agents | 22 | 2024 | 14678 | 0.610 |
Why?
|
| Fetal Blood | 9 | 2023 | 503 | 0.610 |
Why?
|
| Tacrolimus | 9 | 2023 | 351 | 0.600 |
Why?
|
| Prognosis | 48 | 2024 | 22452 | 0.590 |
Why?
|
| Siblings | 6 | 2024 | 299 | 0.580 |
Why?
|
| Cell- and Tissue-Based Therapy | 12 | 2023 | 381 | 0.570 |
Why?
|
| Vincristine | 16 | 2023 | 1572 | 0.570 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2017 | 550 | 0.560 |
Why?
|
| Postoperative Care | 1 | 2020 | 729 | 0.550 |
Why?
|
| Cytomegalovirus Infections | 3 | 2019 | 484 | 0.540 |
Why?
|
| Histocompatibility | 7 | 2018 | 182 | 0.520 |
Why?
|
| Hodgkin Disease | 8 | 2022 | 1486 | 0.520 |
Why?
|
| Genetic Therapy | 5 | 2017 | 1732 | 0.510 |
Why?
|
| Graft Survival | 11 | 2017 | 1091 | 0.500 |
Why?
|
| Burkitt Lymphoma | 4 | 2023 | 350 | 0.480 |
Why?
|
| Neoplasms | 10 | 2024 | 15849 | 0.480 |
Why?
|
| Lymphoma | 7 | 2023 | 1514 | 0.480 |
Why?
|
| Hemorrhage | 2 | 2021 | 742 | 0.480 |
Why?
|
| Antigen-Presenting Cells | 7 | 2016 | 289 | 0.480 |
Why?
|
| HLA Antigens | 6 | 2024 | 575 | 0.480 |
Why?
|
| Transplantation, Haploidentical | 6 | 2024 | 159 | 0.480 |
Why?
|
| B-Lymphocytes | 5 | 2022 | 1424 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 4507 | 0.450 |
Why?
|
| Follow-Up Studies | 27 | 2023 | 15237 | 0.450 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10349 | 0.450 |
Why?
|
| Bone Marrow Transplantation | 7 | 2024 | 1773 | 0.440 |
Why?
|
| Child | 33 | 2023 | 30328 | 0.440 |
Why?
|
| Models, Biological | 3 | 2019 | 3225 | 0.430 |
Why?
|
| Ganciclovir | 1 | 2013 | 194 | 0.430 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 567 | 0.430 |
Why?
|
| Antigens, CD34 | 5 | 2024 | 642 | 0.420 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 4 | 2018 | 218 | 0.410 |
Why?
|
| Combined Modality Therapy | 19 | 2020 | 9040 | 0.410 |
Why?
|
| Antiviral Agents | 3 | 2016 | 1251 | 0.410 |
Why?
|
| Risk Factors | 28 | 2024 | 17819 | 0.400 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2012 | 94 | 0.390 |
Why?
|
| Fusion Proteins, bcr-abl | 5 | 2023 | 1144 | 0.390 |
Why?
|
| Doxorubicin | 15 | 2023 | 3138 | 0.390 |
Why?
|
| Immunosuppressive Agents | 11 | 2018 | 1442 | 0.380 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2017 | 1836 | 0.380 |
Why?
|
| Leukemia | 6 | 2017 | 1720 | 0.380 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 5 | 2015 | 770 | 0.370 |
Why?
|
| Receptors, Cytokine | 3 | 2023 | 183 | 0.360 |
Why?
|
| Immunotherapy | 5 | 2021 | 3532 | 0.360 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 74 | 0.360 |
Why?
|
| BK Virus | 1 | 2011 | 126 | 0.360 |
Why?
|
| Tissue Donors | 4 | 2024 | 812 | 0.350 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 126 | 0.350 |
Why?
|
| Age Factors | 13 | 2024 | 5485 | 0.350 |
Why?
|
| Incidence | 10 | 2024 | 5838 | 0.340 |
Why?
|
| Mycophenolic Acid | 5 | 2022 | 156 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2019 | 410 | 0.340 |
Why?
|
| Pyridazines | 2 | 2024 | 319 | 0.340 |
Why?
|
| Bone Marrow | 8 | 2021 | 2434 | 0.330 |
Why?
|
| Transposases | 4 | 2013 | 69 | 0.330 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2024 | 841 | 0.330 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2399 | 0.320 |
Why?
|
| Immunologic Factors | 3 | 2021 | 670 | 0.310 |
Why?
|
| Drug Therapy, Combination | 6 | 2022 | 2364 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 5 | 2018 | 271 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 382 | 0.290 |
Why?
|
| Rituximab | 7 | 2023 | 1589 | 0.290 |
Why?
|
| Maintenance Chemotherapy | 3 | 2024 | 224 | 0.280 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 30941 | 0.280 |
Why?
|
| Biological Products | 4 | 2023 | 316 | 0.280 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 365 | 0.280 |
Why?
|
| Imidazoles | 2 | 2024 | 1059 | 0.270 |
Why?
|
| Translocation, Genetic | 5 | 2023 | 1287 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2024 | 1345 | 0.270 |
Why?
|
| Child, Preschool | 14 | 2023 | 16907 | 0.270 |
Why?
|
| Receptors, Complement 3b | 2 | 2022 | 20 | 0.270 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2023 | 104 | 0.260 |
Why?
|
| Immunophenotyping | 4 | 2017 | 1730 | 0.260 |
Why?
|
| Steroids | 4 | 2021 | 376 | 0.260 |
Why?
|
| Benzoates | 2 | 2024 | 130 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2019 | 287 | 0.250 |
Why?
|
| Heterocyclic Compounds | 3 | 2015 | 119 | 0.250 |
Why?
|
| Azacitidine | 3 | 2024 | 1215 | 0.250 |
Why?
|
| Myeloproliferative Disorders | 2 | 2023 | 881 | 0.240 |
Why?
|
| Lymphocyte Activation | 6 | 2016 | 1733 | 0.240 |
Why?
|
| Hydrazines | 2 | 2024 | 214 | 0.240 |
Why?
|
| Cytokines | 4 | 2017 | 2836 | 0.240 |
Why?
|
| Red-Cell Aplasia, Pure | 2 | 2016 | 50 | 0.240 |
Why?
|
| Craniospinal Irradiation | 2 | 2017 | 133 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2018 | 5102 | 0.230 |
Why?
|
| ABO Blood-Group System | 2 | 2016 | 132 | 0.230 |
Why?
|
| Prospective Studies | 15 | 2024 | 13343 | 0.230 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2021 | 1021 | 0.230 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2021 | 996 | 0.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2020 | 2474 | 0.230 |
Why?
|
| Toxoplasmosis | 1 | 2024 | 49 | 0.230 |
Why?
|
| Thiazoles | 4 | 2014 | 729 | 0.220 |
Why?
|
| Neutrophils | 4 | 2017 | 870 | 0.220 |
Why?
|
| Primary Myelofibrosis | 2 | 2023 | 902 | 0.220 |
Why?
|
| Clinical Trials as Topic | 8 | 2019 | 3859 | 0.220 |
Why?
|
| Genetic Vectors | 4 | 2020 | 1884 | 0.220 |
Why?
|
| Methotrexate | 7 | 2023 | 1026 | 0.210 |
Why?
|
| Photopheresis | 2 | 2021 | 79 | 0.210 |
Why?
|
| Electroporation | 6 | 2013 | 127 | 0.210 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2023 | 2312 | 0.210 |
Why?
|
| Lymphocyte Transfusion | 3 | 2017 | 174 | 0.200 |
Why?
|
| Gene Transfer Techniques | 5 | 2017 | 812 | 0.200 |
Why?
|
| Infusions, Intravenous | 4 | 2013 | 1437 | 0.200 |
Why?
|
| Pyrimidines | 7 | 2014 | 3666 | 0.200 |
Why?
|
| Killer Cells, Natural | 4 | 2024 | 958 | 0.200 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2024 | 186 | 0.200 |
Why?
|
| Thalidomide | 3 | 2016 | 600 | 0.190 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.190 |
Why?
|
| Disease Management | 2 | 2018 | 1109 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2023 | 4385 | 0.190 |
Why?
|
| Gene Rearrangement | 2 | 2023 | 817 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2015 | 1372 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2016 | 1666 | 0.190 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.190 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2021 | 1919 | 0.190 |
Why?
|
| Retreatment | 3 | 2016 | 450 | 0.180 |
Why?
|
| Pentostatin | 2 | 2017 | 121 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 99 | 0.180 |
Why?
|
| Interleukin-15 | 2 | 2024 | 189 | 0.180 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 13976 | 0.180 |
Why?
|
| Blood Platelets | 3 | 2015 | 682 | 0.180 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 1379 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 2421 | 0.170 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 985 | 0.170 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 618 | 0.170 |
Why?
|
| Dasatinib | 5 | 2015 | 881 | 0.170 |
Why?
|
| Aniline Compounds | 1 | 2021 | 206 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 1467 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2023 | 2345 | 0.170 |
Why?
|
| CD3 Complex | 4 | 2013 | 322 | 0.170 |
Why?
|
| Cytarabine | 8 | 2019 | 2014 | 0.170 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 19 | 0.170 |
Why?
|
| CD28 Antigens | 4 | 2013 | 204 | 0.170 |
Why?
|
| Cause of Death | 3 | 2017 | 784 | 0.160 |
Why?
|
| Frailty | 1 | 2021 | 129 | 0.160 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 3 | 2017 | 60 | 0.160 |
Why?
|
| POEMS Syndrome | 1 | 2018 | 23 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2022 | 1269 | 0.160 |
Why?
|
| Anticoagulants | 2 | 2022 | 785 | 0.160 |
Why?
|
| Haplotypes | 3 | 2018 | 848 | 0.160 |
Why?
|
| History, 21st Century | 1 | 2020 | 420 | 0.160 |
Why?
|
| Plasmids | 3 | 2016 | 952 | 0.160 |
Why?
|
| Ehrlichia chaffeensis | 1 | 2018 | 11 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2019 | 6248 | 0.160 |
Why?
|
| Ehrlichiosis | 1 | 2018 | 19 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 333 | 0.160 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2015 | 38 | 0.160 |
Why?
|
| Expert Testimony | 1 | 2018 | 84 | 0.150 |
Why?
|
| Frail Elderly | 2 | 2021 | 123 | 0.150 |
Why?
|
| Thymus Neoplasms | 1 | 2023 | 420 | 0.150 |
Why?
|
| Prednisone | 2 | 2018 | 1039 | 0.150 |
Why?
|
| Cytomegalovirus | 2 | 2019 | 493 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2021 | 587 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2019 | 93 | 0.150 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 81 | 0.150 |
Why?
|
| Quinolines | 1 | 2021 | 402 | 0.150 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2018 | 40 | 0.150 |
Why?
|
| Time Factors | 10 | 2020 | 13102 | 0.150 |
Why?
|
| Proportional Hazards Models | 7 | 2023 | 5085 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2024 | 1542 | 0.150 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 3538 | 0.150 |
Why?
|
| Transgenes | 2 | 2017 | 589 | 0.150 |
Why?
|
| Geriatric Assessment | 2 | 2021 | 291 | 0.150 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 74 | 0.140 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 154 | 0.140 |
Why?
|
| Graft Rejection | 3 | 2018 | 865 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Neutropenia | 1 | 2021 | 1001 | 0.140 |
Why?
|
| Propensity Score | 4 | 2021 | 774 | 0.140 |
Why?
|
| Mortality | 2 | 2018 | 353 | 0.140 |
Why?
|
| Virus Activation | 1 | 2019 | 236 | 0.140 |
Why?
|
| Chimerism | 1 | 2017 | 65 | 0.140 |
Why?
|
| Bayes Theorem | 3 | 2022 | 1036 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 251 | 0.140 |
Why?
|
| Preoperative Period | 2 | 2017 | 349 | 0.140 |
Why?
|
| Body Fluids | 1 | 2017 | 124 | 0.140 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 88 | 0.140 |
Why?
|
| Nitriles | 1 | 2021 | 943 | 0.130 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2016 | 50 | 0.130 |
Why?
|
| Receptors, KIR | 1 | 2016 | 63 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2016 | 68 | 0.130 |
Why?
|
| Secondary Prevention | 2 | 2021 | 321 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 630 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 121 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 230 | 0.130 |
Why?
|
| Cryptococcosis | 1 | 2016 | 70 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2023 | 4835 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 263 | 0.130 |
Why?
|
| Simplexvirus | 1 | 2016 | 180 | 0.130 |
Why?
|
| Cytogenetic Analysis | 5 | 2020 | 574 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 286 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 871 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 227 | 0.130 |
Why?
|
| Pancytopenia | 1 | 2016 | 119 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2023 | 2560 | 0.130 |
Why?
|
| Liver Failure, Acute | 1 | 2016 | 98 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 60 | 0.120 |
Why?
|
| Immunotoxins | 1 | 2015 | 120 | 0.120 |
Why?
|
| Bortezomib | 3 | 2022 | 553 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2018 | 579 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 326 | 0.120 |
Why?
|
| K562 Cells | 5 | 2013 | 345 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 356 | 0.120 |
Why?
|
| Liver | 3 | 2024 | 3123 | 0.120 |
Why?
|
| Risk Assessment | 6 | 2024 | 6829 | 0.120 |
Why?
|
| Leukemia, Myeloid | 2 | 2010 | 994 | 0.120 |
Why?
|
| Weight Gain | 1 | 2017 | 475 | 0.120 |
Why?
|
| Cranial Nerve Diseases | 1 | 2014 | 77 | 0.110 |
Why?
|
| Genetic Engineering | 2 | 2014 | 299 | 0.110 |
Why?
|
| Blood Preservation | 1 | 2014 | 60 | 0.110 |
Why?
|
| Cohort Studies | 8 | 2024 | 9427 | 0.110 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2013 | 36 | 0.110 |
Why?
|
| Carmustine | 3 | 2019 | 224 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 3073 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 595 | 0.110 |
Why?
|
| Alopecia Areata | 1 | 2014 | 53 | 0.110 |
Why?
|
| Deoxyribonucleases | 1 | 2013 | 55 | 0.110 |
Why?
|
| Piperazines | 4 | 2013 | 2153 | 0.110 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 791 | 0.110 |
Why?
|
| Tissue Engineering | 1 | 2015 | 253 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2017 | 590 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2014 | 243 | 0.110 |
Why?
|
| Homologous Recombination | 1 | 2014 | 187 | 0.110 |
Why?
|
| Adenoviridae Infections | 1 | 2013 | 114 | 0.100 |
Why?
|
| Leukemia, B-Cell | 1 | 2013 | 114 | 0.100 |
Why?
|
| Fertility Preservation | 1 | 2014 | 158 | 0.100 |
Why?
|
| Blood Donors | 2 | 2010 | 173 | 0.100 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 4330 | 0.100 |
Why?
|
| Cells, Cultured | 5 | 2013 | 5780 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 246 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2014 | 671 | 0.100 |
Why?
|
| Transplantation Immunology | 3 | 2019 | 109 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2023 | 852 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2015 | 315 | 0.100 |
Why?
|
| Alleles | 2 | 2015 | 2507 | 0.100 |
Why?
|
| Social Support | 1 | 2014 | 585 | 0.100 |
Why?
|
| Sample Size | 1 | 2012 | 206 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 1268 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2024 | 1335 | 0.090 |
Why?
|
| Animals | 13 | 2024 | 62754 | 0.090 |
Why?
|
| Aminoglycosides | 2 | 2012 | 235 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2018 | 5411 | 0.090 |
Why?
|
| Clonal Anergy | 1 | 2010 | 12 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 549 | 0.090 |
Why?
|
| Patient Safety | 1 | 2016 | 651 | 0.090 |
Why?
|
| Treatment Failure | 4 | 2017 | 1432 | 0.090 |
Why?
|
| Texas | 4 | 2017 | 6412 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 196 | 0.090 |
Why?
|
| Plasma Cells | 2 | 2023 | 202 | 0.090 |
Why?
|
| Genotype | 2 | 2016 | 4110 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 120 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2040 | 0.090 |
Why?
|
| Leukapheresis | 3 | 2022 | 166 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1053 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2011 | 267 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2014 | 785 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2280 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1323 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2009 | 48 | 0.090 |
Why?
|
| Epitopes | 1 | 2012 | 711 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2024 | 212 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2012 | 425 | 0.080 |
Why?
|
| Vaccines | 1 | 2014 | 395 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 236 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 2984 | 0.080 |
Why?
|
| Comorbidity | 3 | 2023 | 2430 | 0.080 |
Why?
|
| Etoposide | 3 | 2018 | 905 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2012 | 621 | 0.080 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 475 | 0.080 |
Why?
|
| Benzylamines | 3 | 2015 | 101 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2009 | 182 | 0.080 |
Why?
|
| Vaccination | 1 | 2014 | 1147 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2009 | 295 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 779 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 737 | 0.080 |
Why?
|
| Ferritins | 2 | 2021 | 154 | 0.070 |
Why?
|
| Blood Component Removal | 1 | 2008 | 121 | 0.070 |
Why?
|
| Flow Cytometry | 4 | 2016 | 3083 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2023 | 1849 | 0.070 |
Why?
|
| Mice | 7 | 2024 | 35988 | 0.070 |
Why?
|
| Hematopoiesis | 1 | 2011 | 606 | 0.070 |
Why?
|
| Disease Progression | 5 | 2024 | 6891 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 4124 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 870 | 0.070 |
Why?
|
| Quality of Life | 4 | 2023 | 4731 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 880 | 0.070 |
Why?
|
| Stromal Cells | 1 | 2011 | 840 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 2669 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 636 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 1228 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 2198 | 0.070 |
Why?
|
| Cell Culture Techniques | 3 | 2014 | 580 | 0.070 |
Why?
|
| Genes, Transgenic, Suicide | 2 | 2017 | 63 | 0.070 |
Why?
|
| Dendritic Cells | 2 | 2023 | 1108 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 347 | 0.070 |
Why?
|
| Melanoma | 1 | 2023 | 5523 | 0.070 |
Why?
|
| United States | 6 | 2023 | 15978 | 0.060 |
Why?
|
| Monosomy | 2 | 2017 | 98 | 0.060 |
Why?
|
| Coculture Techniques | 3 | 2013 | 635 | 0.060 |
Why?
|
| Antilymphocyte Serum | 3 | 2012 | 237 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3657 | 0.060 |
Why?
|
| Imatinib Mesylate | 4 | 2013 | 1691 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2011 | 706 | 0.060 |
Why?
|
| Deoxycytidine | 3 | 2018 | 1377 | 0.060 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.060 |
Why?
|
| Fatal Outcome | 2 | 2016 | 837 | 0.060 |
Why?
|
| Pyridines | 1 | 2011 | 1311 | 0.060 |
Why?
|
| Transplantation Chimera | 2 | 2015 | 173 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 988 | 0.060 |
Why?
|
| Benzamides | 4 | 2013 | 1883 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2024 | 82 | 0.060 |
Why?
|
| Tandem Repeat Sequences | 1 | 2024 | 202 | 0.060 |
Why?
|
| Filgrastim | 3 | 2009 | 194 | 0.060 |
Why?
|
| Europe | 2 | 2015 | 646 | 0.060 |
Why?
|
| Mutant Chimeric Proteins | 2 | 2013 | 25 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 2335 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 2848 | 0.060 |
Why?
|
| Autografts | 1 | 2023 | 179 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2019 | 1346 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 3653 | 0.050 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 204 | 0.050 |
Why?
|
| Polyamines | 1 | 2022 | 80 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1055 | 0.050 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 105 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2023 | 171 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1914 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2002 | 75 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 1995 | 541 | 0.050 |
Why?
|
| Gene Duplication | 1 | 2024 | 433 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 4505 | 0.050 |
Why?
|
| Certification | 1 | 2023 | 109 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 106 | 0.050 |
Why?
|
| Zinc Fingers | 2 | 2013 | 222 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2005 | 503 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4981 | 0.050 |
Why?
|
| Mutation | 4 | 2018 | 15842 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 3492 | 0.050 |
Why?
|
| Adoptive Transfer | 2 | 2014 | 435 | 0.050 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 9 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3544 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 1259 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 596 | 0.050 |
Why?
|
| Thiotepa | 2 | 2012 | 132 | 0.050 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2019 | 8 | 0.040 |
Why?
|
| Germinal Center | 1 | 2021 | 168 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2015 | 738 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7808 | 0.040 |
Why?
|
| Karyotyping | 2 | 2012 | 1064 | 0.040 |
Why?
|
| Cholagogues and Choleretics | 1 | 2019 | 38 | 0.040 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2019 | 55 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2022 | 452 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 14864 | 0.040 |
Why?
|
| Genes, abl | 1 | 2019 | 120 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2019 | 65 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 418 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Retroviridae | 1 | 2020 | 376 | 0.040 |
Why?
|
| Ascites | 1 | 2020 | 216 | 0.040 |
Why?
|
| Asparaginase | 1 | 2019 | 185 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2018 | 52 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 323 | 0.040 |
Why?
|
| Age of Onset | 1 | 2021 | 821 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1119 | 0.040 |
Why?
|
| Bilirubin | 1 | 2019 | 223 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 276 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1318 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 324 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 963 | 0.040 |
Why?
|
| Consensus | 1 | 2023 | 1103 | 0.040 |
Why?
|
| Clonal Evolution | 1 | 2019 | 251 | 0.040 |
Why?
|
| Drug Approval | 1 | 2018 | 178 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2018 | 158 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 7460 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 302 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 88 | 0.040 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 584 | 0.040 |
Why?
|
| Patient Comfort | 1 | 2016 | 7 | 0.040 |
Why?
|
| Foscarnet | 1 | 2016 | 19 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2023 | 1547 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 2490 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 252 | 0.030 |
Why?
|
| Point Mutation | 1 | 2019 | 791 | 0.030 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 68 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2016 | 435 | 0.030 |
Why?
|
| Acyclovir | 1 | 2016 | 80 | 0.030 |
Why?
|
| Transaminases | 1 | 2016 | 82 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 151 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2016 | 70 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 423 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2019 | 337 | 0.030 |
Why?
|
| Biomarkers | 2 | 2019 | 5104 | 0.030 |
Why?
|
| Valine | 1 | 2016 | 184 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 157 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 238 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 200 | 0.030 |
Why?
|
| Rhodamines | 1 | 2015 | 48 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 505 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 1654 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Intercellular Junctions | 1 | 1995 | 56 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 254 | 0.030 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 62 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 371 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1277 | 0.030 |
Why?
|
| Facial Nerve Diseases | 1 | 2014 | 21 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 78 | 0.030 |
Why?
|
| Photosensitizing Agents | 1 | 2015 | 81 | 0.030 |
Why?
|
| Gene Editing | 1 | 2017 | 231 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 109 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 95 | 0.030 |
Why?
|
| P-Selectin | 1 | 2015 | 110 | 0.030 |
Why?
|
| Infant | 3 | 2015 | 13854 | 0.030 |
Why?
|
| Hominidae | 1 | 1994 | 43 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2260 | 0.030 |
Why?
|
| Living Donors | 1 | 2015 | 178 | 0.030 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 167 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1934 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2024 | 6027 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1400 | 0.030 |
Why?
|
| Protons | 1 | 2017 | 483 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1820 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2019 | 1181 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 335 | 0.030 |
Why?
|
| Brain Diseases | 1 | 2017 | 414 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 482 | 0.030 |
Why?
|
| RNA, Messenger | 3 | 2013 | 6483 | 0.030 |
Why?
|
| Photons | 1 | 2017 | 537 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2013 | 254 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 721 | 0.030 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 111 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 671 | 0.030 |
Why?
|
| DNA, Superhelical | 1 | 2013 | 28 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 520 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 459 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 99 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2016 | 421 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2017 | 461 | 0.030 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 228 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2012 | 234 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 6169 | 0.030 |
Why?
|
| Actins | 1 | 1995 | 616 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 524 | 0.030 |
Why?
|
| Enediynes | 1 | 2012 | 13 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2013 | 248 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 605 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 622 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2013 | 289 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2012 | 173 | 0.020 |
Why?
|
| Sex Factors | 1 | 2017 | 2189 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3459 | 0.020 |
Why?
|
| Mucositis | 1 | 2012 | 150 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 129 | 0.020 |
Why?
|
| L-Selectin | 1 | 2011 | 36 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 658 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 1994 | 612 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 272 | 0.020 |
Why?
|
| Endonucleases | 1 | 2012 | 183 | 0.020 |
Why?
|
| Cadherins | 1 | 1994 | 676 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 683 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2023 | 3349 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 284 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 2266 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 247 | 0.020 |
Why?
|
| Glioblastoma | 2 | 2013 | 1777 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 197 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 210 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2314 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 485 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 719 | 0.020 |
Why?
|
| Cell Line | 2 | 2015 | 5435 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 435 | 0.020 |
Why?
|
| Base Sequence | 2 | 2013 | 5494 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1995 | 1327 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 306 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 428 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 891 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1212 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10698 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2013 | 6784 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2013 | 7294 | 0.020 |
Why?
|
| Rabbits | 1 | 2010 | 1089 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1473 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 954 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 911 | 0.020 |
Why?
|
| Interleukins | 1 | 2011 | 340 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1617 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 470 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2009 | 357 | 0.020 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2009 | 107 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 3416 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 601 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 147 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1510 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 113 | 0.020 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 1502 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2500 | 0.020 |
Why?
|
| Leukemic Infiltration | 1 | 2007 | 73 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3436 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1369 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2011 | 1184 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 749 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2012 | 1522 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1994 | 3415 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2016 | 12204 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 345 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1566 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 1150 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 565 | 0.020 |
Why?
|
| alpha Catenin | 2 | 1995 | 23 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5184 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 3172 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1597 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2007 | 322 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3679 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2007 | 458 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 1146 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 2736 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2007 | 1435 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1338 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2006 | 641 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2013 | 4190 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 1024 | 0.010 |
Why?
|
| Algorithms | 1 | 2012 | 3906 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2009 | 1462 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2471 | 0.010 |
Why?
|
| Palliative Care | 1 | 2007 | 2154 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 91 | 0.010 |
Why?
|
| Chickens | 1 | 1994 | 791 | 0.010 |
Why?
|
| Dogs | 1 | 1995 | 1168 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1995 | 1011 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1994 | 498 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 1152 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1994 | 956 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 1091 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1994 | 1460 | 0.010 |
Why?
|
| Phylogeny | 1 | 1994 | 866 | 0.010 |
Why?
|
| Drosophila | 1 | 1994 | 911 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 4641 | 0.000 |
Why?
|